Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients
Medicare officials said they would cover Biogen Inc.’s BIIB 2.64% controversial Alzheimer’s disease drug Aduhelm on the condition that patients...
Centers for Medicare and Medicaid Services
